The cost of Afrezza, an inhaled insulin, varies depending on insurance coverage, pharmacy, and dosage. Without insurance, a 30-day supply of Afrezza can range from $350 to over $500 [1]. Patients with insurance may pay significantly less, with co-pays often falling between $10 and $75 for a 30-day supply, depending on their specific plan [1].
How much does Afrezza cost with different insurance plans?
Insurance coverage for Afrezza is a key factor in its out-of-pocket cost. Many insurance providers offer coverage, but the exact co-pay amount is determined by the formulary and tier the drug is placed on. Some plans may require prior authorization or step therapy, where patients must try other insulins first. Information on specific insurance plans and their coverage for Afrezza can often be found on the manufacturer's website or by contacting the insurance provider directly [1].
Are there Afrezza discount programs or coupons available?
To help mitigate the cost, manufacturers often provide discount programs and coupons for Afrezza. These programs can reduce the co-pay for eligible commercially insured patients, sometimes bringing the monthly cost down to as low as $25 [1]. Patients should check the Afrezza website or consult their pharmacist for information on current savings programs and eligibility requirements.
How does Afrezza's price compare to other inhaled insulins?
Afrezza's pricing is generally comparable to other inhaled insulin products on the market. The cost of inhaled insulins can fluctuate and is influenced by market competition and manufacturer pricing strategies. For instance, Trijio, another inhaled insulin, has a similar price range [2]. When considering the cost, it is important to also factor in the effectiveness and convenience of each option for individual patient needs.
When does Afrezza's patent expire?
The patent protection for Afrezza is a significant factor in its market exclusivity and pricing. According to DrugPatentWatch.com, the key patents related to Afrezza are set to expire in the coming years [3]. For example, U.S. Patent No. 8,703,778, which covers formulations and methods of use, is listed with an expiry date in 2027 [3]. Understanding patent expiry is crucial for anticipating the potential market entry of generic or biosimilar alternatives, which could impact pricing in the future.
What are the potential risks or side effects of Afrezza?
Patients considering Afrezza should be aware of its potential risks and side effects. Common side effects include hypoglycemia (low blood sugar), cough, and throat irritation [4]. A serious risk associated with Afrezza is bronchospasm in patients with chronic lung disease, such as asthma and COPD, and it should not be used in these individuals [4]. It is essential for patients to discuss these risks with their healthcare provider before starting treatment.
Sources:
[1] https://www.goodrx.com/afrezza
[2] https://www.drugpatentwatch.com/drug/trijio/patents
[3] https://www.drugpatentwatch.com/drug/afrezza/patents
[4] https://www.afrezza.com/about-afrezza/safety-information